Stockscreener 앱 받기
35.39
1.90%
0.66
시간 외 거래:
35.39
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
Form 144 ROIVANT SCIENCES LTD. For: 30 June By Investing.com - Investing.com Canada
Is Roivant Sciences (ROIV) Losing Its Defensive Status or Reframing Its Risk Narrative? - simplywall.st
Roivant Sciences Ltd.(NasdaqGS: ROIV) dropped from Russell 1000 Value-Defensive Index - marketscreener.com
Roivant Sciences Ltd.(NasdaqGS: ROIV) dropped from Russell 1000 Defensive Index - marketscreener.com
Roivant Sciences Insider Sold Shares Worth $6,631,268, According to a Recent SEC Filing - Moomoo
Understanding the Setup: (ROIV) and Scalable Risk - Stock Traders Daily
Price to sales forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Enterprise value to revenue forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Enterprise value to revenue forward of Roivant Sciences Ltd. – DUS:87S - TradingView
Enterprise value to EBITDA forward of Roivant Sciences Ltd. – DUS:87S - TradingView
Enterprise value to EBIT forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Form 144 ROIVANT SCIENCES LTD. For: 26 June - Investing.com UK
Form 144 ROIVANT SCIENCES LTD. For: 26 June By Investing.com - Investing.com Nigeria
Price to earnings forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Roivant Sciences(ROIV.US) Officer Sells US$6.63 Million in Common Stock - Moomoo
Roivant (NASDAQ: ROIV) president sells 200K shares, exercises 200K stock options - Stock Titan
Form 144 ROIVANT SCIENCES LTD. For: 25 June - Investing.com UK
Form 144 ROIVANT SCIENCES LTD. For: 25 June By Investing.com - Investing.com South Africa
Roivant Sciences Ltd (ROIV) Institutional Confidence - TradingKey
JNJ Stock Price and Chart — NYSE:JNJ - TradingView
Price to book forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Morgan Stanley Smith Barney files 500,000-share sale (NASDAQ: ROIV) - Stock Titan
Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study - Benzinga
Roivant Sciences stock hits all-time high at 32.8 USD By Investing.com - Investing.com Australia
Roivant Sciences stock hits all-time high at 32.8 USD - Investing.com
Roivant Sciences Ltd (ROIV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Roivant Sciences Ltd (ROIV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Roivant Sciences Ltd. (ROIV) Stock Analysis: Navigating Biotech Opportunities with 24.22% Potential Upside - DirectorsTalk Interviews
Roivant Sciences Ltd (ROIV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
What Roivant Sciences (ROIV)'s $2.25 Billion Moderna Settlement and Immunology Wins Mean For Shareholders - simplywall.st
Roivant Sciences (ROIV) Stock Could Be 19.5% Undervalued After Moderna Settlement And Pipeline Progress - simplywall.st
Roivant Sciences Ltd (ROIV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Roivant Sciences Ltd (ROIV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fidelity Advisor Biotechnology Fund's Roivant Sciences Ltd(ROIV) Holding History - GuruFocus
Roivant Sciences Ltd (ROIV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Roivant Sciences Ltd (ROIV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Roivant Sciences Ltd (ROIV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
The Technical Signals Behind (ROIV) That Institutions Follow - Stock Traders Daily
Here is Why Roivant (ROIV) is One of the Best Growth Stocks Trading in Oversold Territory - Insider Monkey
Analysts’ Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (ENGN), Medtronic (MDT) and Roivant Sciences (ROIV) - The Globe and Mail
Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $40 - Moomoo
12 Best Growth Stocks Trading in Oversold Territory - Insider Monkey
Global Endurance Portfolio's Roivant Sciences Ltd(ROIV) Holding History - GuruFocus
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a Potential 29.97% Upside in Biotech Innovation - DirectorsTalk Interviews
Te Ahumairangi Investment Management Ltd Decreases Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Guggenheim and Citi Raise Roivant Sciences Price Targets After EarningsEarnings Surprise Score - newsline.com
Clearbridge Investments LLC Boosts Stock Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Bank of New York Mellon Corp Has $63 Million Stock Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Transcript : Roivant Sciences Ltd. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11 - marketscreener.com
Roivant gains after mid-stage trial data for Immunovant’s main asset - MSN
Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV) - Insider Monkey
ROIV: Brepocitinib leads a robust pipeline targeting rare diseases, with strong data and launch plans - TradingView
ROIV: Late-stage pipeline advances in rare diseases and immunology, with strong financial flexibility - TradingView
TD Asset Management Inc Purchases 235,176 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts - MSN
588,400 Shares in Roivant Sciences Ltd. $ROIV Purchased by ING Groep NV - MarketBeat
1.79%
0.47%
자본화:
|
볼륨(24시간):